North America Epilepsy Drugs Market Report and Forecast 2024-2032

North America Epilepsy Drugs Market Size

The North America epilepsy drugs market is expected to grow at a CAGR of 4.30% during the forecast period of 2024-2032, driven by increased clinical trials and research initiatives to introduce novel anti-epileptic drugs in the region.

North America Epilepsy Drugs Market Outlook

• One of the major market trends is the rising entry of generic equivalents of popular epilepsy medications.

• The surge in clinical trials to introduce novel epilepsy drugs with better efficacy and minimal side effects is poised to fuel the North America epilepsy drugs market demand.

• In the United States, around 3 million people are reported to suffer from epilepsy. The growing number of epilepsy cases coupled with heightened patient awareness is driving the market growth.

North America Epilepsy Drugs Market Analysis

Epilepsy is a common neurological condition characterized by recurrent seizures. This chronic noncommunicable disease can occur in people of all ages and is known to affect 50 million individuals worldwide. In the United States, around 3 million people are reported to suffer from epilepsy. The growing number of epilepsy cases coupled with the heightened patient awareness is contributing to the global epilepsy drugs market. Further, it is estimated that 70% of epilepsy patients could live seizure-free following appropriate diagnosis and treatment, indicating the need for effective epilepsy drugs. The rising advancements in drug development supported by the increased research funding and robust government initiatives are expected to drive the North America epilepsy drugs market growth.

Growth in clinical trials to introduce novel epilepsy drugs with better efficacy and minimal side effects is poised to shape the market landscape in coming years. In October 2023, the results of a phase 2b clinical trial of Xenon Pharmaceutical’s (a Canadian neuroscience-focused biopharmaceutical company) investigational drug XEN1101 demonstrated a reduction in seizure frequency by more than 50% in certain epilepsy patients and sometimes even eliminated them altogether. The study, conducted by the researchers at NYU Grossman School of Medicine (a medical school of New York University), also showed that the new oral drug can be started at its most effective dose, unlike other epilepsy treatments that have to be gradually ramped up. Increased clinical trial activities focused on evaluating the clinical outcomes of innovative epilepsy therapeutics is projected to boost the market value in the forecast period.

One of the major North America epilepsy drugs market trends is the rising entry of generic equivalents of popular epilepsy medications. For example, in December 2023, an Indian multinational pharmaceutical company Zydus Lifesciences Limited received US Food and Drug Administration (FDA) approval to manufacture and market a generic version of anti-epileptic medication, Lacosamide Tablets, in multiple strengths. The drug is indicated for the treatment of partial-onset seizures and is also used in combination with other medicines to treat primary generalized tonic-clonic seizures. Since generic medications are generally sold at lower prices than brand-name drugs, this market trend is anticipated to increase the accessibility of essential epilepsy treatment options and thereby augment the market demand.

North America Epilepsy Drugs Market Segmentation

The report offers a detailed analysis of the market based on the following segments:

Leading Players in the North America Epilepsy Drugs Market

The key features of the market report include patent analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

UCB SA

UCB (Union Chimique Belge) is a multinational biopharmaceutical company that specializes in the research and development of epilepsy treatments. In March 2022, the U.S. Food and Drug Administration (FDA) approved its drug (branded as Fintepla) to treat seizures associated with a rare form of childhood epilepsy, Lennox-Gastaut Syndrome (LGS).

Novartis AG

This Swiss multinational pharmaceutical corporation's drug asset TRILEPTAL is indicated for monotherapy or adjunctive therapy in adults to treat partial-onset seizures.

Pfizer Inc.

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered in New York City and is actively involved in the development of epilepsy drugs. Its anti-epileptic medication Zarontin (ethosuximide) is used alone or in combination with other medicines to treat absence seizures in adults and children.

GSK Plc

The British multinational pharmaceutical and biotechnology company is known for its oral solution Keppra, indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalization. It can be taken by adults and adolescents 16 years or above with newly diagnosed epilepsy.

Other players in the market include Abbott Laboratories, Sanofi SA, Sumitomo Pharma America Inc., Teva Pharmaceutical Industries Ltd., Catalyst Pharmaceuticals Inc., and Alkem Laboratories Ltd.

Key Highlights of the Report

North America Epilepsy Drugs Market Report Snapshots

North America Epilepsy Drugs Market Size

North America Epilepsy Drugs Market Analysis

North America Epilepsy Drugs Companies